These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30658922)

  • 21. Depression, sleep disturbances, pain, disability and quality of LIFE in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Mol Genet Metab Rep; 2020 Mar; 22():100547. PubMed ID: 31871893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease.
    Avarappattu J; Gaspert A; Spartà G; Rohrbach M
    Pediatr Nephrol; 2024 Jan; 39(1):131-140. PubMed ID: 37470867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social-adaptive and psychological functioning of patients affected by Fabry disease.
    Laney DA; Gruskin DJ; Fernhoff PM; Cubells JF; Ousley OY; Hipp H; Mehta AJ
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S73-81. PubMed ID: 20087663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study.
    Arends M; Körver S; Hughes DA; Mehta A; Hollak CEM; Biegstraaten M
    J Inherit Metab Dis; 2018 Jan; 41(1):141-149. PubMed ID: 29039131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
    Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fabry disease: demographic data since introduction of enzyme replacement therapy].
    Cybulla M; Walter K; Neumann HP; Widmer U; Schärer M; Sunder-Plassmann G; Jansen T; Rolfs A; Beck M
    Dtsch Med Wochenschr; 2007 Jul; 132(28-29):1505-9. PubMed ID: 17607649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
    Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
    Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.
    Hughes DA; Barba Romero MÁ; Hollak CE; Giugliani R; Deegan PB
    Mol Genet Metab; 2011 Jul; 103(3):207-14. PubMed ID: 21543245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurological complications of Anderson-Fabry disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
    Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
    Mac Lochlainn DJ; McKechnie DGJ; Mehta AB; Hughes DA
    Mol Genet Metab; 2018 Feb; 123(2):154-158. PubMed ID: 29055531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
    Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
    Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Musculoskeletal manifestations of Fabry disease: A retrospective study.
    Lidove O; Zeller V; Chicheportiche V; Meyssonnier V; Sené T; Godot S; Ziza JM
    Joint Bone Spine; 2016 Jul; 83(4):421-6. PubMed ID: 26697993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
    Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
    Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
    Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
    Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease.
    Ko Y; Lee C; Moon MH; Hong GR; Cheon CK; Lee JS
    J Hum Genet; 2016 Feb; 61(2):143-9. PubMed ID: 26490183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study on serum IgE and clinical symptomatology of atopy in patients suffering from the lysosomal storage disorder Fabry disease.
    Möhrenschlager M; Ollert M; Ring J
    J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):692-5. PubMed ID: 18384565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ).
    Ramaswami U; Stull DE; Parini R; Pintos-Morell G; Whybra C; Kalkum G; Rohrbach M; Raluy-Callado M; Beck M; Chen WH; Wiklund I;
    Health Qual Life Outcomes; 2012 Sep; 10():116. PubMed ID: 22992222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac manifestations in patients with classical or cardiac subtype of Fabry disease.
    Wang WT; Sung SH; Liao JN; Hsu TR; Niu DM; Yu WC
    J Chin Med Assoc; 2020 Sep; 83(9):825-829. PubMed ID: 32649415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.